Medical News Today: Parabens may increase breast cancer risk in Black women
UC expert comments on implications of recent study
Black women in the United States are 39% more likely to die from breast cancer compared to white women and are more likely to develop breast cancer under the age of 40.
A recent study conducted by researchers at City of Hope in Los Angeles found that compounds called parabens, which are used as preservatives in hair and personal care products, increased the growth of a Black breast cancer cell line but did not increase growth in a white breast cancer cell line.
Xiaoting Zhang, PhD, professor and Thomas Boat Endowed Chair in the University of Cincinnati's Department of Cancer Biology, director of the Breast Cancer Research Program and member of the University of Cincinnati Cancer Center, was not involved in the study but commented on it for Medical News Today.
Zhang said the study findings were interesting and suggest that at least part of the reason why parabens affect cancer cells differently is due to genetic or epigenetic differences.
"It will be highly critical to further study its effect not only in cultured breast cancer cells but also in animal models and eventually in humans,” Zhang said.
Read the Medical News Today story.
Featured photo at top of Dr. Zhang at microscope. Photo/Andrew Higley/UC Marketing + Brand
Related Stories
UC biologist talks about 'pearmageddon'
March 16, 2026
WLWT talks to UC biologist and Department Head Theresa Culley about invasive, nonnative Callery pear trees that are spreading across Ohio forests after they were introduced by landscapers more than 50 years ago.
Local media highlight completion of Blood Cancer Healing Center fourth and fifth floors
March 16, 2026
Local media including WLWT and the Cincinnati Business Courier highlighted the opening of research laboratories and the UC Osher Wellness Suite and Learning Kitchen at the University of Cincinnati Cancer Center’s Blood Cancer Healing Center.
Trial results support weekly buprenorphine treatment of opioid use disorder during pregnancy
March 16, 2026
Supported by the National Institutes of Health (NIH), researchers led by the University of Cincinnati's John Winhusen published clinical trial results in JAMA Internal Medicine that found administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder during pregnancy led to higher rates of abstinence from illicit opioids than buprenorphine given daily under the tongue, one of the standard methods of treatment.